In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:

• Engage key stakeholders in the provision of HBV care​
• Provide HBV management resources to support PCPs who are doing screening​
• Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV

Presenters:

Su Wang, MD, MPH, FACP
Medical Director
Center for Asian Health and Viral Hepatitis Programs
Cooperman Barnabas Medical Center
RWJBarnabas-Rutgers Medical Group
Associate Member
Health Care Policy and Aging Research
The Rutgers Institute for Health
Senior Advisor
Global Health, Hepatitis B Foundation
Florham Park, New Jersey

Richard R. Andrews, MD, MPH
President, Houston Viral Hepatitis Task Force
Former Co-Chair, National Task Force on Hepatitis B
Board-Certified Family Medicine
Addiction Medicine Physician
Houston, Texas

Ruth Brogden, MPH
Patient Advocate

Amy S. Tang, MD
Former Co-Chair, National Task Force on Hepatitis B
Director of Immigrant Health
North East Medical Services
San Francisco, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/44hXpHu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:

• Patient subgroups to consider for treatment outside guideline criteria
• Adverse event and cost-effectiveness considerations
• Integration of patient perspectives in wider treatment

Presenters:

Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Jacki Chen, PhD
Patient Advocate

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides:
https://bit.ly/4a60GM4

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies.

Presenters:

Arun B. Jesudian, MD
Associate Professor of Clinical Medicine
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York

Mazen Noureddin, MD, MHSc
Professor of Medicine
Houston Methodist Hospital
Director
Houston Research Institute
Houston, Texas

Content based on an online CME program supported by independent educational grants from Novo Nordisk.

To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.

Link to full program:
https://bit.ly/3Tyu7At

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:

• Updated CDC recommendations for one-time universal screening for HBV
• Addressing patient-, provider-, and system-level barriers to universal HBV screening
• Best practices for implementation of HDV screening

Presenters:

Douglas Dieterich, MD
Director, Institute for Liver Medicine

Professor of Medicine

Division of Liver Diseases

Mount Sinai School of Medicine

New York, New York

Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Robert Wong, MD, MS 
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California

Link to full program:
https://bit.ly/3TuqFHI

Link to the slides: 
https://bit.ly/4atS42z

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:

• Current COVID-19 landscape
• Rapid antigen tests and PCR tests
• Risk stratification of patients who have a positive SARS-CoV-2 test
• Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
• Long COVID

Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia

To download the slides: bit.ly/3oHKC09

To view the full online program: bit.ly/4201xcO

In this episode, Jona Tanguay, MMSc, PA-C, AAHIVS discusses considerations to review with patients to empower them to make their own informed choices in PrEP selection, including:

• Leveraging PrEP options with unique dosing schedules and/or routes such as long-acting cabotegravir and on-demand 2-1-1 FTC/TDF
• Differences in adverse effect profiles between 4 PrEP options
• Potential for HIV resistance
• Requirements for compliance and monitoring
• Evidence in populations with various acquisition behaviors
• Drug interaction implications

Faculty: 

Jona Tanguay, MMSc, PA-C, AAHIVS

Health Care Provider and HIV Specialist 

Whitman-Walker Health

Vice President for Education, GLMA: Health Professionals Advancing LGBTQ Equality

Clinical Instructor, Yale University School of Nursing 

Washington, DC

Link to full program: https://bit.ly/41WF54o

In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:

• Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplam
• Discussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complications
• Review of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDA

Presenters:

Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts

Supported by an educational grant from Biogen

Link to full program:
bit.ly/41kw2dK

Link to CME: Claim credit -
bit.ly/40fkDKD

In this episode, Dr. Battista and Dr. Parsons discuss the importance of care guidelines and the multidisciplinary team in the treatment of spinal muscular atrophy (SMA). This overview will include:

• The role each member of the interdisciplinary team plays in the care of SMA including physical therapists, occupational therapists, and speech therapists
• The importance of continued, ongoing therapy in addition to medication therapy to provide the greatest improvement in SMA care
• How to manage transitions in care, including the transition from pediatrics to adulthood and how to include the necessary support teams
• The role shared decision-making plays in the treatment of patients with SMA

Presenters:

Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts

Supported by an educational grant from Biogen.

Link to full program: 
https://bit.ly/43Dmo7q

Link to CME: Claim credit
https://bit.ly/40gulfX